ProQR Therapeutics NV
NASDAQ:PRQR

Watchlist Manager
ProQR Therapeutics NV Logo
ProQR Therapeutics NV
NASDAQ:PRQR
Watchlist
Price: 2.09 USD 2.45% Market Closed
Market Cap: 219.9m USD

Wall Street
Price Targets

PRQR Price Targets Summary
ProQR Therapeutics NV

Wall Street analysts forecast PRQR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PRQR is 9.76 USD with a low forecast of 5.05 USD and a high forecast of 14.7 USD.

Lowest
Price Target
5.05 USD
142% Upside
Average
Price Target
9.76 USD
367% Upside
Highest
Price Target
14.7 USD
603% Upside
ProQR Therapeutics NV Competitors:
Price Targets
BIIB
Biogen Inc
1% Upside
UTHR
United Therapeutics Corp
3% Upside
9926
Akeso Inc
44% Upside
QTTB
Homology Medicines Inc
243% Upside
KNSA
Kiniksa Pharmaceuticals Ltd
33% Upside
MDXH
MDxHealth SA
114% Upside
LCTX
Lineage Cell Therapeutics Inc
173% Upside
002252
Shanghai RAAS Blood Products Co Ltd
11% Upside

Revenue
Forecast

Revenue Estimate
ProQR Therapeutics NV

For the last 11 years the compound annual growth rate for ProQR Therapeutics NV's revenue is 59%. The projected CAGR for the next 4 years is 40%.

59%
Past Growth
40%
Estimated Growth
Estimates Accuracy
-4%
Average Miss

Operating Income
Forecast

Operating Income Estimate
ProQR Therapeutics NV

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
9%
Average Beat

Net Income
Forecast

Net Income Estimate
ProQR Therapeutics NV

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-61%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is PRQR's stock price target?
Price Target
9.76 USD

According to Wall Street analysts, the average 1-year price target for PRQR is 9.76 USD with a low forecast of 5.05 USD and a high forecast of 14.7 USD.

What is ProQR Therapeutics NV's Revenue forecast?
Projected CAGR
40%

For the last 11 years the compound annual growth rate for ProQR Therapeutics NV's revenue is 59%. The projected CAGR for the next 4 years is 40%.

Back to Top